Australian biotech market today 05.05.09
Tuesday, 05 May, 2009
The healthcare index is down three per cent today at 2.00pm, bucking the trend of most of the other indices, which were up 0.5 per cent overall.
The trend was predominantly due to falls in the Big Three, with Cochlear (ASX:COH) down $2, CSL (ASX:CSL) down $1 and ResMed (ASX:RMD) down 4c.
Sirtex (ASX:SRX) was down 7c to $3.08 while Sonic Healthcare (ASX:SHL) was down 46c to $11.14.
BioDiem (ASX:BDM) and Avexa (ASX:AVX) were both down to 9 cents each, despite Avexa raising some much needed cash recently.
A bright spot was Pharmaxis (ASX:PXS), up 37c to $2.65 on today’s positive data from its Phase III trial of Bronchitol in cystic fibrosis. Marketing approval in Europe looks certain for this product and the company has others in the pipeline.
Acrux (ASX:ACR) was up 3.5 per cent on small volumes, and Cellestis (ASX:CST) was up a healthy 11c to $2.83. Mesoblast (ASX:MSB) was up 5c on small volumes.
Novel antibiotic activates 'suicide' mechanism in superbug
Researchers have discovered a new class of antibiotic that selectively targets Neisseria...
Modifications in the placenta linked to psychiatric disorders
Schizophrenia, bipolar disorder and major depression disorder are the neuropsychiatric disorders...
ADHD may be linked with an increased risk of dementia
An adult brain affected by attention deficit hyperactivity disorder (ADHD) presents modifications...
